Eli Lilly news and events in 2026
Eli Lilly is a pharmaceutical company that develops and manufactures medicines for global distribution. The organization focuses on biotechnology, chemistry, and genetic medicine to create treatments for type two diabetes, weight loss, obstructive sleep apnea, and various forms of cancer.
Get Eli Lilly's live signals in Claude or ChatGPT, or by API
What changed at Eli Lilly this week? Use Autobound signals for lilly.com.- Dated updates
- 114
- Last event
- Nov 17, 2026
- Open rolesSnapshot Nov 17, 2026
- 495
- Latest SEC filing
- Oct 29, 2026
Source: Autobound Signal API · 114 signals tracked for Eli Lilly · updated
Overview
Eli Lilly by topic
110-K filing
495open roles
77+signals
73 in the last 90 days
- Glassdoor15+
- LinkedIn15+
- Reddit13
- X (Twitter)12
- and 2 more sources
Latest events
Latest Eli Lilly events
Showing 10 of 30 events. The Signal API returns all of them.
Get them with one API call- Investment
- Acquisition
- InvestmentRichter Partners with U.S. Pharma Giant to Advance Women’s Health$15M · With Gedeon Richter
- In developmentNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one...Eli Lilly announced detailed 52-week results from its Phase 3b TOGETHER-PsA clinical trial evaluating the concomitant use of Taltz and Zepbound.
- In developmentLilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight lossEli Lilly and Company announced positive Phase 3 clinical trial results for Foundayo (orforglipron) for the treatment of moderate-to-severe obstructive sleep apnea.
- Partnership
- PartnershipLilly and Hims & Hers expand access to FDA-approved Lilly medicinesWith Hims & Hers Health, Inc.
- EarningsLilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolioEli Lilly and Company reported third-quarter 2026 net income of $6.5 billion.
- In developmentAfter obesity, Eli Lilly is set for a big neurosciences pushEli Lilly is developing remternetug, a phase III investigational amyloid-targeting therapy for subcutaneous delivery to treat Alzheimer's disease.
- In developmentLilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trialEli Lilly and Company announced positive topline results from the Phase 3 TRANSCEND-T2D-2 clinical trial evaluating retatrutide in adults with type 2 diabetes.
Showing 10 of 30 events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Eli Lilly with the Signal API
One POST /v1/companies/enrich call with lilly.com returns every signal type for Eli Lilly, each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"lilly.com","limit":20}'Bulk data
Need these signals for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file).
Same industry
Companies related to Eli Lilly
Eli Lilly questions
What is the latest news on Eli Lilly?
What is going on with Eli Lilly?
Has Eli Lilly announced any acquisitions?
What else does Autobound track for Eli Lilly?
Is Eli Lilly hiring right now?
Page updated , the date of the newest row on this page.
Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.
Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.
Data as of .